Specialty: Metabolic and endocrine disorders, Primary sub-specialty: Metabolic and endocrine disorders
Conditions
Interventions
This will be a multicentre study across 6 UK centres (Newcastle upon Tyne, Gateshead, Exeter, Cardiff, Oxford and Leeds).
Phase 1: Refinement of DiaGO and reproducibility:
This phase includes an in
Sponsors
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosis of GD 2. Hyperthyroidism/subclinical hyperthyroidism and smooth, symmetrical goitre or positive TSH receptor antibodies 3. Euthyroid/hypothyroid/hyperthyroid and positive TSH receptor antibodies
Exclusion criteria
Exclusion criteria: 1. People with Graves' Disease already reviewed by ophthalmology 2. Remain under the care of ophthalmology with GO 3. Children under 18 years of age
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity and specificity of DiaGO using initial DiaGO data (at baseline, assessment in Endocrine clinic) and diagnosis of GO at six months (after assessment in ophthalmology clinic). | — |
Secondary
| Measure | Time frame |
|---|---|
| Ease of use of DiaGO by endocrinologists and its acceptability at baseline by a user questionnaire Whether use of DiaGO results in earlier employment of treatments to manage GO by clinical records review at six months. | — |
Countries
United Kingdom
Outcome results
None listed